Table 3.
Risk factors of more severe COVID-19 course – univariate analysis
| GROUP | n | OR | 95% CI | p-value |
|---|---|---|---|---|
| Age per 10y | 924 | 2.16 | 1.63, 2.84 | <0.001 |
| Male | 923 | 1.93 | 1.07, 3.44 | 0.026 |
| One or more comorbidities | 924 | 2.77 | 1.56, 4.96 | <0.001 |
| Cardiac comorbidity | 910 | 4.49 | 1.84, 9.86 | <0.001 |
| Pulmonary comorbidity | 912 | 4.24 | 1.37, 10.9 | 0.005 |
| Diabetes | 912 | 3.37 | 0.77, 10.6 | 0.060 |
| Ever smoker (former/current) | 833 | 1.37 | 0.65, 2.68 | 0.37 |
| BMI | 744 | 1.08 | 1.02, 1.13 | 0.003 |
| EDSS | 910 | |||
| EDSS < 4 | — | — | ||
| EDSS >= 4 | 2.42 | 1.34, 4.32 | 0.003 | |
| DMT category | 921 | |||
| A. DMT except for anti-CD20 | — | — | ||
| B. No current DMT | 2.79 | 1.24, 5.84 | 0.009 | |
| C. Anti-CD20 | 7.44 | 3.70, 14.6 | <0.001 | |
| MS duration, y | 920 | 1.04 | 1.01, 1.07 | 0.003 |
| High dose glucocorticoid therapy during the 2 months before COVID-19 onset | 882 | 3.49 | 1.52, 7.32 | 0.002 |
OR = odds ratio, CI = confidence interval, BMI = body mass index, EDSS = expanded disability status scale, DMT = disease modifying therapy, Anti-CD20 = ocrelizumab and rituximab